Stephanie Davis
Stock Analyst at Barclays
(0.58)
# 4,142
Out of 5,124 analysts
94
Total ratings
31.82%
Success rate
-109.82%
Average return
Main Sectors:
Stocks Rated by Stephanie Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DGX Quest Diagnostics | Maintains: Equal-Weight | $190 → $195 | $173.53 | +12.37% | 7 | Oct 22, 2025 | |
| WAY Waystar Holding | Maintains: Overweight | $50 → $45 | $32.75 | +37.40% | 6 | Apr 14, 2025 | |
| OPRX OptimizeRx | Maintains: Equal-Weight | $11 → $5 | $12.26 | -59.22% | 3 | Nov 14, 2024 | |
| DOCS Doximity | Maintains: Overweight | $52 → $75 | $44.28 | +69.38% | 5 | Nov 11, 2024 | |
| LFST LifeStance Health Group | Maintains: Underweight | $6 → $7 | $7.04 | -0.57% | 2 | Nov 11, 2024 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $10 → $6 | $2.71 | +121.40% | 7 | Nov 11, 2024 | |
| EVH Evolent Health | Maintains: Overweight | $39 → $19 | $4.00 | +375.00% | 1 | Nov 11, 2024 | |
| COR Cencora | Maintains: Overweight | $263 → $290 | $337.75 | -14.14% | 2 | Nov 7, 2024 | |
| CAH Cardinal Health | Maintains: Overweight | $117 → $133 | $205.50 | -35.28% | 2 | Nov 4, 2024 | |
| OMCL Omnicell | Maintains: Equal-Weight | $39 → $58 | $45.30 | +28.04% | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $3 | $3.63 | -17.36% | 7 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $213 → $249 | $250.88 | -0.75% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $29 | $16.92 | +71.39% | 11 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $7.00 | +385.71% | 9 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $59 → $34 | $25.68 | +32.40% | 3 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $242 → $233 | $223.23 | +4.38% | 9 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $17 | $2.39 | +611.30% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $76 | $91.61 | -17.04% | 5 | Jun 7, 2022 |
Quest Diagnostics
Oct 22, 2025
Maintains: Equal-Weight
Price Target: $190 → $195
Current: $173.53
Upside: +12.37%
Waystar Holding
Apr 14, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $32.75
Upside: +37.40%
OptimizeRx
Nov 14, 2024
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $12.26
Upside: -59.22%
Doximity
Nov 11, 2024
Maintains: Overweight
Price Target: $52 → $75
Current: $44.28
Upside: +69.38%
LifeStance Health Group
Nov 11, 2024
Maintains: Underweight
Price Target: $6 → $7
Current: $7.04
Upside: -0.57%
GoodRx Holdings
Nov 11, 2024
Maintains: Overweight
Price Target: $10 → $6
Current: $2.71
Upside: +121.40%
Evolent Health
Nov 11, 2024
Maintains: Overweight
Price Target: $39 → $19
Current: $4.00
Upside: +375.00%
Cencora
Nov 7, 2024
Maintains: Overweight
Price Target: $263 → $290
Current: $337.75
Upside: -14.14%
Cardinal Health
Nov 4, 2024
Maintains: Overweight
Price Target: $117 → $133
Current: $205.50
Upside: -35.28%
Omnicell
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $39 → $58
Current: $45.30
Upside: +28.04%
Oct 29, 2024
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $3.63
Upside: -17.36%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $213 → $249
Current: $250.88
Upside: -0.75%
Jan 3, 2024
Initiates: Overweight
Price Target: $29
Current: $16.92
Upside: +71.39%
Feb 23, 2023
Upgrades: Outperform
Price Target: $34
Current: $7.00
Upside: +385.71%
Jan 5, 2023
Downgrades: Market Perform
Price Target: $59 → $34
Current: $25.68
Upside: +32.40%
Dec 2, 2022
Maintains: Outperform
Price Target: $242 → $233
Current: $223.23
Upside: +4.38%
Nov 9, 2022
Maintains: Outperform
Price Target: $20 → $17
Current: $2.39
Upside: +611.30%
Jun 7, 2022
Maintains: Outperform
Price Target: $67 → $76
Current: $91.61
Upside: -17.04%